Lv Yi Song, Yao You Sheng, Rong Lu, Lin Ming En, Deng Bi Hua, Xie Yun, Huang Hai, Lin Tian Xin, Xu Ke Wei, Huang Jian
Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Department of Urology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Int J Urol. 2014 Jun;21(6):601-7. doi: 10.1111/iju.12358. Epub 2013 Nov 28.
To determine whether a potential rat model of bladder pain syndrome could be developed through long-term intermittent intravesical hyaluronidase.
A total of 64 female Sprague-Dawley rats were divided into a control group, a low-dose hyaluronidase (1 mg/mL) group, a high-dose hyaluronidase (4 mg/mL) group and a hyaluronic acid-treated group. Hyaluronidase was given intravesically three times a week for 1 month. Hyaluronic acid (0.5 mL, 0.8 mg/mL) was introduced intravesically to hyaluronidase-treated rats' bladders. Histological changes, cystometry, nociceptive behaviors, and messenger ribonucleic acid levels of inflammatory factors were evaluated and compared between groups.
All hyaluronidase-treated rats showed chronic inflammation and fibrosis, increased and activated mast cells, thinned bladder epithelium with abnormal expressions of uroplakin III and zonula occluden-1, and increased levels of interleukin-6 and intercellular adhesion molecule-1 messenger ribonucleic acid. However, the inflammatory score and levels of interleukin-6 and intercellular adhesion molecule-1 were more significant in the high-dose hyaluronidase group than in the low-dose hyaluronidase group (P < 0.01). Furthermore, hyaluronidase-treated rats showed markedly decreased intercontraction intervals, bladder capacity and increased sensitivity to pain compared with controls (P < 0.01). Hyaluronic acid treatment significantly decreased the inflammatory level, number of mast cells, sensitivity to pain, levels of interleukin-6 and intercellular adhesion molecule-1, and increased intercontraction intervals and bladder capacity (P < 0.01).
Long-term intermittent intravesical hyaluronidase could develop a severe chronic cystitis with diffused fibrosis accompanied by altered histology and bladder function. This chronic cystitis rat model can resemble the clinical and histopathological features of human bladder pain syndrome, and might be a potential valuable model for investigation of this troublesome disease.
确定能否通过长期间歇性膀胱内注射透明质酸酶建立膀胱疼痛综合征的潜在大鼠模型。
将64只雌性Sprague-Dawley大鼠分为对照组、低剂量透明质酸酶(1 mg/mL)组、高剂量透明质酸酶(4 mg/mL)组和透明质酸处理组。每周膀胱内注射透明质酸酶3次,持续1个月。将透明质酸(0.5 mL,0.8 mg/mL)注入经透明质酸酶处理的大鼠膀胱。评估并比较各组的组织学变化、膀胱测压、伤害性反应行为及炎症因子信使核糖核酸水平。
所有经透明质酸酶处理的大鼠均出现慢性炎症和纤维化,肥大细胞增多且活化,膀胱上皮变薄,尿路上皮蛋白III和闭合蛋白-1表达异常,白细胞介素-6和细胞间黏附分子-1信使核糖核酸水平升高。然而,高剂量透明质酸酶组的炎症评分以及白细胞介素-6和细胞间黏附分子-1水平比低剂量透明质酸酶组更显著(P < 0.01)。此外,与对照组相比,经透明质酸酶处理的大鼠的收缩间期明显缩短,膀胱容量减小,对疼痛的敏感性增加(P < 0.01)。透明质酸处理显著降低了炎症水平、肥大细胞数量、疼痛敏感性、白细胞介素-6和细胞间黏附分子-1水平,并增加了收缩间期和膀胱容量(P < 0.01)。
长期间歇性膀胱内注射透明质酸酶可导致严重的慢性膀胱炎,并伴有弥漫性纤维化,同时组织学和膀胱功能发生改变。这种慢性膀胱炎大鼠模型可模拟人类膀胱疼痛综合征的临床和组织病理学特征,可能是研究这种疑难疾病的潜在有价值模型。